Patient Characteristics and Safety of Lecanemab in a Large Community‐Based Cohort at Sutter Health

Our data show that lecanemab can be safely delivered in a large community-based healthcare system. Compared to the phase 3 CLARITY-AD trial, we report higher rates of infusions related reactions but lower rates of ARIA. Our cohort contains fewer ApoE4 homozygotes (6%) compared to CLARITY-AD (16%) which likely reduces our ARIA rates. However, we observe lower rates of ARIA in ApoE4 non-carriers and ApoE4 heterozygotes compared to CLARITY-AD, supporting that lecanemab can be safely administered in a community setting.